Skip to content

Study · Animal study (in vivo) · 2016

6 results

Humanin exerts cardioprotection against cardiac ischemia/reperfusion injury through attenuation of mitochondrial dysfunction.

Thummasorn S, Apaijai N, Kerdphoo S, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N

Cardiovascular therapeutics1 Dec 2016Cited by 53 (Europe PMC)

PMID27434747 (opens in a new tab)DOI10.1111/1755-5922.12210 (opens in a new tab)PepBankPUB-27434747
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In an I/R injury model, humanin analogue pretreatment decreased arrhythmia incidence.

    In plain wordsIn animals with heart injury, pretreatment with a humanin analogue reduced irregular heartbeats.

    Peptide
    Humanin
    Outcome
    DecreaseArrhythmia incidence after I/R
    Study

    n: not reported in source

    Coronary artery occlusion and reperfusion (I/R) injury
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN analogue pretreatment decreased arrhythmia incidence and infarct size, improved cardiac mitochondrial function, and attenuated cardiac dysfunction.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an I/R injury model, humanin analogue pretreatment decreased infarct size.

    In plain wordsIn animals with heart injury, pretreatment with a humanin analogue reduced the size of heart tissue damage.

    Peptide
    Humanin
    Outcome
    DecreaseInfarct size after I/R
    Study

    n: not reported in source

    Coronary artery occlusion and reperfusion (I/R) injury
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN analogue pretreatment decreased arrhythmia incidence and infarct size, improved cardiac mitochondrial function, and attenuated cardiac dysfunction.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In an I/R injury model, humanin analogue pretreatment improved cardiac mitochondrial function.

    In plain wordsIn animals with heart injury, pretreatment with a humanin analogue improved heart mitochondrial function.

    Peptide
    Humanin
    Outcome
    IncreaseCardiac mitochondrial function after I/R
    Study

    n: not reported in source

    Coronary artery occlusion and reperfusion (I/R) injury
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN analogue pretreatment decreased arrhythmia incidence and infarct size, improved cardiac mitochondrial function, and attenuated cardiac dysfunction.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In an I/R injury model, humanin analogue pretreatment attenuated cardiac dysfunction.

    In plain wordsIn animals with heart injury, pretreatment with a humanin analogue reduced loss of heart function.

    Peptide
    Humanin
    Outcome
    DecreaseCardiac dysfunction after I/R
    Study

    n: not reported in source

    Coronary artery occlusion and reperfusion (I/R) injury
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN analogue pretreatment decreased arrhythmia incidence and infarct size, improved cardiac mitochondrial function, and attenuated cardiac dysfunction.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 05AnimalEndogenous levelAnimal study (in vivo)Other

    In an I/R injury model, natural plasma humanin did not differ between groups before I/R injury.

    In plain wordsIn animals with heart injury, the body's own humanin levels did not differ between groups before the injury.

    Peptide
    Humanin
    Outcome
    No significant changePlasma humanin before I/R injury
    Study

    n: not reported in source

    Coronary artery occlusion and reperfusion (I/R) injury
    Comparator
    Between groups before I/R
    Outcome group
    Aging markers · Cardiovascular

    Source sentences

    Summary
    Endogenous HN level before I/R injury showed no difference between groups

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

  2. 06AnimalEndogenous levelAnimal study (in vivo)Other

    In an I/R injury model, natural plasma humanin was markedly decreased after I/R injury.

    In plain wordsIn animals with heart injury, the body's own humanin levels fell markedly after the injury.

    Peptide
    Humanin
    Outcome
    DecreasePlasma humanin after I/R injury
    Study

    n: not reported in source

    Coronary artery occlusion and reperfusion (I/R) injury
    Comparator
    Before I/R injury
    Outcome group
    Aging markers · Cardiovascular

    Source sentences

    Summary
    but was markedly decreased after I/R injury.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.